The next wave of psychedelics focuses on brain rewiring without the trip [Drug Discovery News]
Wednesday, February 18, 2026 1 min read
Key Takeaway: The article discusses the evolving landscape of psychedelics, particularly their potential to rewire the brain without the hallucinogenic effects. Clinical trials have demonstrated their effectiveness in treating mental health issues such as depression, anxiety, and PTSD. However, the article also notes that there are still concerns regarding the use of these substances.
Price reaction · baseline $2.08 (2026-02-17 close) · hit pre-market · 5 other ENVB headline(s) in the window, move may be shared
day 0 close
+7.7%
day 1 · peak
+16.3%
day 3
-1%
Market Sentiment Analysis
POSITIVE FACTORS
Psychedelics show promise in reshaping the brain.
Potential to improve mental health conditions.
Clinical trials indicate effectiveness for various disorders.
CONCERNS & RISKS
There is still a potential downside to using psychedelics.
Full Press Release Details
For decades, psychedelics like psilocybin and N,N-dimethyltryptamine (DMT) have intrigued scientists and clinicians with their ability to rapidly reshape the brain and improve mental health. Clinical trials have shown promise for conditions ranging from depression and anxiety to post-traumatic stress disorder (PTSD), but there is still a potential downside.
Full Article >>
Frequently Asked Questions
What are psychedelics being studied for?
Psychedelics are being studied for their potential to improve mental health conditions.
What conditions might psychedelics help treat?
They show promise for conditions like depression, anxiety, and PTSD.
Do psychedelics have any downsides?
Yes, there are potential downsides to using psychedelics.
How do psychedelics affect the brain?
They can rapidly reshape the brain and improve mental health.